Abstract.
Bisphosphonates, therapeutic reagents against tumoral bone diseases (Paget's disease or osteoporosis), are potent inhibitors of bone resorption. The mechanisms by which they directly act on mature osteoclasts remain unclear. Using a recently developed technique for isolation of highly purified mammalian mature osteoclasts, we demonstrated that etidronate [ethane-1-hydroxy-1,1-diphosphonate (EHDP), 1-hydroxy-1,1-ethylidenebisphosphonate], inhibited directly osteoclastic bone-resorbing activity by pit assay. In addition, EHDP also directly induced apoptosis and disrupted actin rings in osteoclasts. The data support previous data on non-purified osteoclasts and results in vivo.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 26 June 1997 / Accepted: 27 July 1998
Rights and permissions
About this article
Cite this article
Hiroi-Furuya, E., Kameda, T., Hiura, K. et al. Etidronate (EHDP) Inhibits Osteoclastic-Bone Resorption, Promotes Apoptosis and Disrupts Actin Rings in Isolate-Mature Osteoclasts. Calcif Tissue Int 64, 219–223 (1999). https://doi.org/10.1007/s002239900606
Issue Date:
DOI: https://doi.org/10.1007/s002239900606